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Abstract 
Whilst the role of the Disrupted-in-Schizophrenia 1 (DISC1) gene in the aetiology of major mental illnesses is 
debated, the characterisation of its function lends it credibility as a candidate. A key aspect of this functional 
characterisation is the determination of the role of common non-synonymous polymorphisms on normal 
variation within these functions. The common allele (A) of the DISC1 SNP rs821616 encodes a serine at the 
Ser704Cys polymorphism, and has been shown to increase the phosphorylation of extracellular signal-
regulated protein Kinases 1 and 2 (ERK1/2) which stimulate the phosphorylation of tyrosine hydroxylase, the 
rate-limiting enzyme for dopamine biosynthesis. We therefore set out to test the hypothesis that human A 
(serine) homozygotes would show elevated dopamine synthesis capacity compared to individuals cysteine 
hetero/homozygotes (AT or TT genotype) for rs821616. [18F]-DOPA PET was used to index striatal 
dopamine synthesis capacity as the influx rate constant Kicer in healthy volunteers DISC1 rs821616 serine 
homozygotes (N=46) and healthy volunteers DISC1 rs821616 cysteine carrierscysteine hetero/homozygotes 
(N=56), matched for age, gender, ethnicity and using three scanners. We found DISC1 rs821616 serine 
homozygotes exhibited a significantly higher striatal Kicer compared to cysteine carrierscysteine 
hetero/homozygotes (p-value=0.012) explaining 6.4% of the variance (partial eta squared=0.064). Our finding 
is consistent with its previous association with heightened activation of ERK1/2, which stimulates tyrosine 
hydroxylase activity for dopamine synthesis. This could be a potential mechanism mediating risk for 
psychosis, lending further credibility to the fact that DISC1 is of functional interest in the aetiology of major 
mental illness. 
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Introduction 1 
The dopamine hypothesis has been a leading theory underlying the neurobiology of schizophrenia for 2 
the last four decades (1, 2). The hypothesis was initially based on evidence showing that antipsychotic 3 
medications block dopamine receptors (3-5) and that drugs increasing dopamine levels elicit psychotic 4 
symptoms in healthy people (6-8) and people with schizophrenia (9, 10). Using [18F] fluoro-3,4-5 
dihydroxyphenyl-L-alanine (F-DOPA) Positron Emission Tomography (PET), increased presynaptic 6 
dopamine synthesis capacity has been found in schizophrenia (11), people with prodromal psychotic 7 
symptoms (12, 13) and those with clinical progression to psychosis (14). Whilst a substantial body of 8 
evidence supports the role of increased presynaptic dopamine synthesis capacity in the pathoaetiology 9 
of psychosis, little is known about how genetic factors affect the implicated dopamine system(s) (15). 10 
 11 
The Disrupted-in-Schizophrenia 1 (DISC1) gene was originally discovered at the breakpoint of a 12 
balanced t(1;11) (q42;q14.3) translocation in a Scottish family with a high-prevalence of psychiatric 13 
disorders including schizophrenia (16-18). Further evidence for a link between DISC1 and psychotic 14 
and affective disorders emerged from the follow-up of families displaying rare DISC1 mutations (19, 15 
20) and large family-based studies in the population isolate of Finland (21-23) although a large meta-16 
analysis of families did not observe linkage at this region (24). Furthermore, evidence from individual 17 
population-based cohorts has been inconsistent (25, 26) leading to ongoing debate on its involvement 18 
in schizophrenia (27, 28). Whilst this controversy remains unresolved, there is value in seeking 19 
convergent evidence via studies elucidating the functional impact of the gene and its variations (29-20 
32). DISC1 is a scaffold protein involved in a wide range of neuronal functions including neuro-21 
signalling (30, 33). Preclinical studies show that DISC1 variant models exhibit increased 22 
amphetamine-induced dopamine release in the ventral striatum (see (34-37) reviewed in (38), 23 
indicating that DISC1 variations might affect presynaptic dopamine synthesis capacity. 24 
 25 
 4 
One of the most studied DISC1 single nucleotide polymorphisms (SNPs) is rs821616 which is a non-26 
synonymous mutation leading to the translation of a serine (A allele) or a cysteine (T allele) at codon 27 
704 in exon 11 (39). Importantly, this polymorphism represents therefore not only a variation at the 28 
genetic sequence level but also at the protein sequence level of DISC1. At a molecular level, 29 
Hashimoto et al. (2006) found that overexpression of the serine variant of codon 704 by viral 30 
transduction resulted in a significant increase in phosphorylated ERK1/2, the more biologically active 31 
form (40). ERK1/2 in turn regulates the state of phosphorylation of tyrosine hydroxylase, the rate-32 
limiting enzyme for dopamine biosynthesis, to increase its activity and subsequent dopamine synthesis 33 
by up to two-fold (41-44). Dopamine is synthesized by converting first tyrosine into dihydroxyphenyl-34 
L-alanine (L-DOPA) by tyrosine hydroxylase, and second dihydroxyphenyl-L-alanine (L-DOPA) into 35 
dopamine by aromatic acid decarboxylase (45). [18F]-DOPA PET signal reflects aromatic acid 36 
decarboxylase function and dopamine storage capacity (45), but not directly tyrosine hydroxylase 37 
function. However, it should be noted that 1) tyrosine hydroxylase is the rate limiting step for 38 
dopamine synthesis capacity (43) and 2) the topological distribution of the [18F]-DOPA signal 39 
correlates highly with tyrosine hydroxylase immunostaining in unilaterally 6- hydroxydopamine (6-40 
OHDA)-lesioned rats, thus indicating that the [18F]-DOPA signal is strongly influenced by 41 
endogenous dopamine formed by tyrosine hydroxylase (46). 42 
 43 
In summary, preclinical findings suggest that the Ser704Cys variation affects dopamine synthesis by 44 
regulating ERK1/2 and its control over tyrosine hydroxylase activity. However, it remains unknown 45 
whether the Ser704Cys variation is associated with altered dopamine synthesis in humans. The aim of 46 
this study was therefore to test the hypothesis that serine homozygotes would exhibit increased striatal 47 
dopamine synthesis capacity relative to cysteine carrierscysteine hetero/homozygotes. 48 
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Results 49 
Demographics, scan parameters including the injected dose and substance use characteristics are 50 
shown in table 1. A total of 46 serine homozygotes and 56 cysteine carrierscysteine 51 
hetero/homozygotes (which encompass 45 heterozygotes and 11 cysteine homozygotes) were included 52 
in the study. The genotype frequencies (shown in table 1) did not significantly deviate from Hardy–53 
Weinberg equilibrium (χ2 =1.422 with p=0.233), with a Minor Allele Frequency (T allele) of 0.335. 54 
Age (year) and Kicer (1/min) in the whole striatum were normally distributed across the two groups 55 
whereas injected dose (MBq) was not. There was no significant difference in age between groups 56 
t(100)=1.588, p=0.115 (independent t test) and no significant difference in injected dose p=0.408 57 
(Mann Whitney test). Levene’s test indicated no difference between the variances in the two groups, 58 
F=0.398, p=0.529. The univariate ANCOVA showed that the main effect of the DISC1 SNP rs821616 59 
on the dopamine synthesis capacity in the whole striatum was significant, F (1,96) = 6.555, p=0.012, 60 
partial eta squared =0.064. The effects of the covariates were: for scanner, F(1,96)=16.573, p<0.01, 61 
partial eta squared =0.147, age, F(1,96)=1.056, p=0.307, partial eta squared =0.011, gender, 62 
F(1,96)=0.114, p=0.736, partial eta squared=0.001, ethnicity, F(1,96)=0.061, p=0.805, partial eta 63 
squared=0.001. 64 
65 
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Discussion 66 
In line with our hypothesis, we found that participants with the AA genotype (serine homozygotes 67 
(AA genotype)) forof the Ser704Cys functional DISC1 polymorphism exhibited a significantly greater 68 
Kicer value in the whole striatum, indicating greater dopamine synthesis capacity compared to cysteine 69 
hetero/homozygotes (AT or TT genotype)T (cysteine) carriers. This result is in accordance with 70 
preclinical evidence showing that the serine 704 DISC1 variant increases the activity of ERK1/2, 71 
which in turn enhances the phosphorylation of tyrosine hydroxylase, the rate limiting step in dopamine 72 
synthesis (41, 47). 73 
Limitations 74 
The main limitation of this study was that we used data from three different PET scanners, which 75 
could add error variance. However, scanner was included as a covariate to adjust for this. Furthermore, 76 
the effect of the Ser704Cys polymorphism remained significant when we only included subjects from 77 
PET scanner 2 (F(1,28) = 5.273, p=0.029 (N=16 cysteine carrierscysteine hetero/homozygotes, N=17 78 
serine homozygotes)), but not PET scanner 1 only (F(1,30) = 0.766, p=0.388, (N=19 cysteine 79 
carrierscysteine hetero/homozygotes, N=16 serine homozygotes)) and PET scanner 3 only (F(1,29) = 80 
0.426, p=0.519, (N=21 cysteine carrierscysteine hetero/homozygotes, N=13 serine homozygotes)). It 81 
is important to recognise that we measured the final step in the synthesis of dopamine, the conversion 82 
of L-DOPA into dopamine via aromatic acid decarboxylase (AADC). However, the parameter 83 
measured could be affected by other variables including the uptake of L-DOPA into the brain, 84 
although this should be controlled for by the reference region and there is no a priori reason to 85 
consider that this should be affected by the DISC1 protein. Importantly, this polymorphism was 86 
chosen based on a specific prior hypothesis. Although there was evidence to reject the null hypothesis, 87 
the p-value would not survive genome-wide correction and therefore the result requires replication. 88 
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Implications for mental disorders 89 
The Ser704Cys polymorphism has been associated with schizophrenia with an odds ratio in the range 90 
of 1.3 – 4.18 in various populations including European (48), mixed European/African-American (49), 91 
and Chinese Han (50-52). Inconsistencies have been found, with some studies indicating increased 92 
risk associated with the A allele (serine) (48, 51), whilst others the T (cysteine) allele (50, 52) and no 93 
association found (25) mainly in the Japanese population (53-55). A recent meta-analysis has also 94 
reported association of the A (serine) allele with schizophrenia in Chinese (OR=1.338) and Japanese 95 
populations (OR=1.524), as well as in the overall mixed race sample (56). The inconsistencies in these 96 
results might be due to different ethnic populations. It should be noted that ever expanding studies of 97 
European ancestry population level genetic variants in schizophrenia continually demonstrate no 98 
significant associations at the entire DISC1 locus (57, 58), although there is evidence implicating the 99 
DISC1 interactor phosphodiesterase 4B (PDE4B) as a genome-wide significant single gene locus in a 100 
recent large schizophrenia genome-wide association study (GWAS) (58). Whilst GWAS have made 101 
crucial advances in the understanding of the genetic of schizophrenia, the biological mechanisms 102 
directly underlying the disorder remain yet poorly elucidated (59-61). In this context, the DISC1 103 
protein has been suggested as a biological candidate of interest for investigating molecular 104 
mechanisms of mental illnesses at the protein levels (33, 62). Beyond studies of dichotomous 105 
diagnoses, the serine allele has also been associated with increased risk for poor concentration among 106 
Korean patients with schizophrenia (63), increased severity of positive symptoms and hallucinations in 107 
European patients with First-Episode Psychosis (64) and increased lifetime severity of delusions in 108 
European patients with schizophrenia (65). A potential mechanism for the increased risk could be by 109 
dysregulating the control of dopamine to lead to increased dopamine synthesis. Findings in prodromal 110 
populations show that increased dopamine synthesis is associated with increased risk for psychosis 111 
(12, 13). The difference in dopamine synthesis capacity we observe here between serine homozygotes 112 
and carriers of the alternative allele is much smaller than the differences seen in at risk subjects (14, 113 
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66). It is therefore likely that the Ser704Cys variant interacts with other genetic changes to mediate 114 
risk, potentially by affecting dopamine synthesis.  115 
 116 
The fact that the common serine allele has been described as the risk allele is compatible with 117 
schizophrenia GWAS, in which approximately 50% of the implicated index SNPs are the more 118 
common alleles (67). At the population level, the genetic susceptibility to schizophrenia is caused by a 119 
few rare variants of high penetrance (mainly copy number variants and translocations) and many 120 
common variants of small penetrance (SNPs and variable number of tandem repeats) (68). As each 121 
SNP very minimally impacts schizophrenia risk and is compatible with modern models of natural 122 
selection (67), it is expected that other genetic factors are needed, in the same individual, to increase 123 
the liability to a point of schizophrenia onset. For example, the Ser704Cys site affects interaction with 124 
nuclear distribution element-like 1 (NDEL1) and its homolog Nuclear Distribution Element 1 (NDE1, 125 
also known as NudE) (69, 70), and there is evidence for an interaction between NDEL1 rs1391768 126 
and the Ser704 allele and the NDE1 rs3784859 and the Cys704 allele on the risk for schizophrenia in 127 
European participants (71). Ser704Cys is also the binding site for proteins such as kendrin (also 128 
known as pericentrin PCNT) and Pericentriolar material 1 (PCM1) (72), which have been both 129 
described as risk factor genes for schizophrenia (73). Furthermore, environmental factors such as 130 
exposure to psychosocial stress may also interact with the Ser704Cys polymorphism to affect 131 
dopamine function and mediate risk for schizophrenia (15). Interestingly, using a transgenic 132 
expression of truncated human Disc1 protein with dominant-negative effect, Niwa et al. have shown 133 
that an interaction between DISC1 and stress exposure, as a 3 week social isolation paradigm, 134 
increased dopamine release after amphetamine challenge (34) and induced alterations in DNA 135 
methylation of the tyrosine hydroxylase gene (74). 136 
 137 
Evidence also suggests that the Ser704Cys polymorphism is a risk factor for affective disorders. The 138 
cysteine allele has been associated with major depression in Japanese population (47), and shown to 139 
form a protective haplotype for bipolar spectrum disorder with two others DISC1 SNPs (rs1411771 140 
 9 
and rs980989) in Finnish population (75), whereas a higher serine allele rate has been found in South 141 
Indian population with bipolar disorder (76). Interestingly, increased dopamine synthesis capacity is 142 
seen in both mania (77) and bipolar psychosis (78), whilst major depression with affective flattening 143 
is characterized by a decreased synthesis capacity (79, 80). 144 
 145 
The Ser704Cys SNP has also been shown to have a functional impact at the brain level (39). 146 
Compared to healthy cysteine carrierscysteine hetero/homozygotes, serine homozygotes display 147 
increased (for the same level of performance, thus putatively inefficient) prefrontal cortex activation in 148 
the left middle and left superior frontal gyri and in the homologous right superior frontal gyrus, the left 149 
inferior frontal and cingulate cortex, the thalamus and the caudate nucleus in a verbal fluency task 150 
(81), as well as an effect on thalamic-prefrontal connectivity (82). Ser704Cys SNP has also been 151 
shown to affect activation during declarative memory task with inconsistent findings. Callicott et al 152 
(48) found decreased activation bilaterally in the hippocampal formation during a declarative memory 153 
task and increased activation bilaterally in the hippocampal formation in an N-back task in Ser704 154 
homozygotes controls compared to cysteine carrierscysteine hetero/homozygotes, whereas Di Giorgio 155 
et al (83) found increased hippocampal formation/dorsolateral prefrontal cortex coupling during 156 
memory encoding in a declarative memory task in serine homozygotes compared to healthy cysteine 157 
carrierscysteine hetero/homozygotes. 158 
 159 
In summary, our results provide unprecedented preliminary evidence that DISC1 Ser704Cys has an 160 
impact on the dopamine synthesis capacity, in a large sample of 102 healthy volunteers. Further 161 
studies should aim at 1) replicating this result in different cohorts; 2) investigating potential epistatic 162 
interactions with DISC1 and other risk genes. Genetic studies based on molecular evidence could help 163 
identify the molecular mechanism that underlies the pathoaetiology of dopamine-related disorders 164 
such as psychotic disorders, and help identify novel potential treatment targets (15). 165 
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Conclusion 166 
We found that the serine allele of DISC1 Ser704Cys (rs821616) was associated with significantly 167 
higher striatal dopamine synthesis capacity, consistently with its previous association with heightened 168 
activation of ERK1/2 which stimulates tyrosine hydroxylase activity for dopamine synthesis. This 169 
implicates the DISC1 polymorphism in altering a psychosis relevant mechanism in the brain i.e. the 170 
facilitation of greater dopamine synthesis capacity. Although, this effect of rs821616 may be of too 171 
small effect to be identified in population-based studies of end state diagnoses at their current large 172 
size, it continues to implicate the functional role of DISC1. Firstly by highlighting the role of this 173 
polymorphism at this gene in creating variation within the normal functioning of the brain, but also by 174 
indicating this function as a potential mechanism through which other rare or familial mutations for 175 
major mental illnesses could disrupt functioning and increase risk to these devastating disorders. 176 
177 
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Material and Methods 178 
Overview 179 
All participants gave informed written consent to take part after full description of the study. All 180 
studies were approved by the institutional review board and the local research ethics committee. 181 
Participants 182 
Participants were recruited via advertisement in local media based in London. One hundred and 183 
twenty-three participants underwent a [18F]-DOPA PET scan. For all participants the inclusion criteria 184 
were 1) age above 18 years; 2) capacity to give written informed consent. The exclusion criteria were 185 
1) any current medical conditions or history of medical condition (past minor self-limiting conditions 186 
were permitted); 2) history of a psychiatric disorder as determined by the Structured Clinical Interview 187 
for DSM-IV Axis 1 Disorders, Clinician Version (SCID-CV) (84); 3) history of substance 188 
abuse/dependence as determined by the Structured Clinical Interview for DSM-IV Axis 1 Disorders, 189 
Clinician Version (SCID-CV) (84); 4) history of head injury with a loss of consciousness; 5) a family 190 
history of any psychotic disorder in first- or second-degree relatives; 6) contraindications to positron 191 
emission tomography (PET) scanning (significant prior exposure to radiation, pregnancy or breast 192 
feeding). All participants provided urine samples prior to the scan to screen for drug use and 193 
pregnancy test in women. Six participants were excluded due to positive urine THC screening, 12 194 
participants were excluded to contamination of samples and 3 participants were excluded due to 195 
current psychotropic medication use. This resulted in the final inclusion of 102 participants (46 196 
females/56 males, age: 30.2±9.3 years (mean±Standard Deviation SD)). Both scanning and imaging 197 
analysis were done blind to the genotype status. 198 
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[18F]-FDOPA PET 199 
PET data were acquired using three different PET scanners. PET scanner 1 was an ECAT HR+ 962 200 
PET scanner (CTI/Siemens, Knoxville, Tennessee). The dynamic images were acquired in 3D mode 201 
with an axial field of view of 15.5 cm and reconstructed using filterback projection. PET scanners 2 202 
and 3 were two Siemens Biograph HiRez XVI PET-CT scanner (Siemens Healthcare, Erlangen, 203 
Germany) at Imanova, Centre for Imaging Sciences. PET scanner 1 and PET scanner 2-3 were 204 
identical with the only exception of the axial field of view: 16.2 cm vs 21.6 cm respectively. The 205 
dynamic images were also reconstructed using a 3D filtered back-projection algorithm (discrete 206 
inverse Fourier transform, DIFT) with a 128 matrix, a zoom of 2.6 and a 5mm isotropic Gaussian 207 
smoothing. Participants were scanned at various times of the day. Some of the imaging data has been 208 
included in prior reports but not for genetic analysis (85-88). For attenuation and model-based scatter 209 
correction, a 10 min transmission scan was performed using a 150-MBq cesium-137 rotating point 210 
source for the ECAT HR+ 962 PET scanner and a computed tomography scan (effective 211 
dose=0.36 mSv) for the Siemens Biograph HiRez XVI PET-CT scanners were acquired prior to each 212 
PET scan. Experimental protocol was consistent for all the participants (85). Participants were asked 213 
to fast and abstain from smoking from midnight on the day of the scan as tobacco use has been 214 
associated with increased striatal dopamine synthesis capacity (89) although this has not been 215 
replicated (85). Oral doses of carbidopa (150mg) and entacapone (400mg) were administrated 1hour 216 
before scanning. While the first reduces the peripheral metabolism of the tracer (90), the latter 217 
minimizes the formation of radiolabeled [18F]-FDOPA metabolites, which can cross the blood-brain 218 
barrier (91). Head movement was monitored and minimized with a light head strap. If participants 219 
moved extensively during the acquisition or got out of the scanner a second attenuation correction 220 
image was acquired at the end of the acquisition. PET data were acquired dynamically during 95 221 
minutes after bolus injection of the radioactive tracer [18F]-DOPA through a cannula inserted into a 222 
vein. Dynamic data were binned into 26 frames (PET scanner 1) and 32 frames (PET scanner 2 and 3). 223 
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Image Analysis 224 
Head movement was corrected using a frame-by-frame realignment and denoising algorithm (92) with 225 
a level 2 order 64 Battle-Lemarie wavelet filter applied on the non- attenuation-corrected dynamic 226 
images. These images were used because they include a significant scalp signal compared to 227 
attenuation-corrected images (93). Frames were realigned to a reference frame corresponding to the 228 
frame with the highest number of counts, i.e. obtained 7 minutes (for the ECAT HR+ 962 PET 229 
scanner-CTI/Siemens, Knoxville, Tennessee) and 17 minutes (for the Siemens Biograph HiRez XVI 230 
PET-CT scanners-Siemens Healthcare, Erlangen, Germany) after the radiotracer injection using a 231 
mutual information algorithm (94). The transformation parameters were then applied to the 232 
corresponding attenuation-corrected dynamic images. These realigned frames were summated, 233 
creating a movement-corrected dynamic image from which to extract the Time Activity Curves (TAC) 234 
for graphical analysis quantification. Standardized regions in Montreal Neurologic Institute (MNI) 235 
space were defined in the whole striatum delineated as previously described to create a Region of 236 
Interest (ROI) map (95) and in the cerebellum using the probabilistic Martinez atlas (95, 96). The 237 
cerebellum was used as a reference region as it is largely devoid of dopaminergic neurons or 238 
projections (45). A nonlinear transformation procedure on SPM8 (http://www.fil.ion.ucl.ac.uk/spm) 239 
was used to normalize the ROI map together with the [18F]-DOPA template to each individual PET 240 
summation image, in order to place the ROI automatically on individual [18F]-DOPA PET dynamic 241 
images. Influx constant Kicer value, (min-1) for the whole striatum was calculated relative to uptake in 242 
the reference region using a graphical approach (97), a method which has been shown to have good 243 
reliability (95). 244 
Genetic analysis 245 
DNA was extracted from blood or cheek swabs using standard methods (98). Genotyping of the 246 
rs821616 A>T SNP, was performed by KBioscience (Herts, UK, http://www.kbioscience.co.uk) using 247 
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a competitive allele specific Polymerase Chain Reaction system (CASP). Quality control procedures 248 
included negative control (water) wells and duplicate wells.  249 
Statistical analysis 250 
The normality of the distribution for all variables was examined using the Shapiro Wilk test, 251 
inspection of Q-Q plots and skewness and kurtosis values within range of ± 2. Homogeneity of 252 
variance was assessed with Levene’s Test for Equality of Variances. An alpha threshold was set at 253 
0.05 (two-tailed) for significance for all statistical comparisons. Statistical Package for the Social 254 
Sciences (SPSS) version 24 was used for all statistical analysis (IBM, Armonk, N.Y.). All data are 255 
shown as mean±SD. An univariate analysis of covariance (ANCOVA) was performed on 102 healthy 256 
controls, with the DISC1 SNP Ser704Cys variation (serine homozygotes versus cysteine 257 
carrierscysteine hetero/homozygotes) as the independent variable, Kicer in the whole striatum as the 258 
dependent variable and age, gender, ethnicity (table 1) and the three PET scanners separately as 259 
covariates as these variables have been previously found to influence dopamine synthesis capacity (99, 260 
100). Effect sizes are reported as partial eta squared. Independent t test and Mann-Whitney test were 261 
used to compare age and injected dose. 262 
263 
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Legend to Figure 609 
Figure 1: Mean (SEM) striatal dopamine synthesis capacity (Kicer value, min-1) in DISC1 rs821616 cysteine carrierscysteine 610 
hetero/homozygotes (TT and TA, N=56) and DISC1 rs821616 serine homozygotes (AA, N=46). Dopamine synthesis 611 
capacity was significantly increased in serine homozygotes compared with cysteine carrierscysteine hetero/homozygotes (F 612 
(1,96)=6.555, p=0.012). 613 
614 
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Table 615 
Table 1   DISC1 SNP rs821616   
  Total AT and TTcysteine 
hetero/homozygotes 
carriers 
serine AA 
homozygotesca
rriers 
P value 
Total genotype counts 102 45 (AT) and 11 (TT) 46 (AA)  
Females 46 21 25 
PET scanner 1 35 19 16  
0.549 iii PET scanner 2 33 16 17 
PET scanner 3 34 21 13 
    
 
Age 30.2 (9.3) 31.5 (9.9) 28.6 (8.4) 0.115 i 
Tobacco smoking 
status (nonsmoker) 
75 43 32  
0.411 ii 
Tobacco smoking 
status (smoker) 
27 13 14 
Radioactivity injected 
(MBq) 
157.7 (16.2) 156.6 (16.2) 159.2 (16.4) 0.529 ii 
White European 70 35 35  
 
 
0.503 iii 
Black British/other 22 15 7 
Asian British/other 5 3 2 
Mixed ethnicity 5 3 2 
All data ± SD. 
i Independent t test 
ii
 Mann-Whitney U test 
iii
 Pearson Chi-Square 
 616 
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